Researchers evaluated the anticancer effect of ACY-241, an HDAC6-selective inhibitor, on erlotinib-resistant pancreatic cancer cells that overexpressed HDAC6.
[Archives of Pharmacal Research]
Sorry, but the selected Zotpress account can't be found.
Sorry, but the selected Zotpress account can't be found.